ReviewHeart rhythm O22022
Management of atrial fibrillation in rheumatic heart disease.
Review in Heart rhythm O2, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- 2023 KASNet Guidelines on Atrial Fibrillation Surgery.Journal of chest surgery · 2024Guideline
- Medical, interventional, and surgical management of rheumatic heart disease.Lancet regional health. Americas · 2026Review
- Acute rheumatic fever and rheumatic heart disease.Nature reviews. Disease primers · 2026Review
- Editorial Comment: Non-Vitamin K Antagonist Oral Anticoagulants for Thromboembolic Prevention in Patients with Atrial Fibrillation and Concomitant Mitral Stenosis: A Retrospective Observational Study.Acta Cardiologica Sinica · 2025Article
- Anticoagulation use in rheumatic heart disease-associated atrial fibrillation: a study of real-world practice in Central Australia.International journal of cardiology. Heart & vasculature · 2025Article
- 2025 THRS Expert Consensus of Imaging Assessment in Atrial Fibrillation.Acta Cardiologica Sinica · 2025Article
- Magnitude and associated factors of atrial fibrillation, and its complications among adult rheumatic heart diseases patients in governmental hospitals in Bahir Dar Town, Northwest Ethiopia 2024.BMC cardiovascular disorders · 2025Article
- Temporal trends in mortality involving atrial fibrillation and rheumatic heart disease: a 25-year nationwide analysis.Frontiers in cardiovascular medicine · 2025Article
- Prevalence, Management, and Outcomes of Atrial Fibrillation in Paediatric Patients: Insights from a Tertiary Cardiology Centre.Medicina (Kaunas, Lithuania) · 2024Article
- Recent Advances in the Management of Non-rheumatic Atrial Fibrillation: A Comprehensive Review.Cureus · 2024Review
- Lateral medullary syndrome resulting from atrial fibrillation due to rheumatic heart disease: A case report and literature review.Clinical case reports · 2024Article
- Revisiting percutaneous balloon mitral valvotomy technique and safety in various population: an evidence-based case report and literature review.Frontiers in cardiovascular medicine · 2024Article
- Special issue on electrophysiology and arrhythmia management around the globe: Challenges and opportunities explored.Heart rhythm O2 · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatic heart disease (RHD) is the underlying cause of a significant proportion of atrial fibrillation (AF) in the low- and middle-income countries, while nonvalvular AF is the most common cause of AF in high-income countries. RHD is also common among African Americans, migrants, and the indigenous population of high-income countries. The onset of AF in RHD patients is a clinical marker of worse outcomes and is associated with significant morbidity and mortality. Despite RHD being a major cause of morbidity and mortality in the young in many parts of the world, it is often neglected by policymakers, the media, and even the medical fraternity. Stroke risk assessment using various risk scores has not been systematically evaluated in rheumatic AF patients. Rate control may not be ideal for symptom control in rheumatic AF patients considering the young age and an active lifestyle. There is limited information regarding the nonpharmacological management of rheumatic AF. The current management guidelines based on nonvalvular AF do not apply to rheumatic AF patients who are often younger, are women, and have fewer comorbidities. This review critically looks at specific areas such as stroke prevention with reference to direct oral anticoagulants, cardioversion, rate and rhythm control strategies, and the role of nonpharmacological methods in rheumatic AF management. Future recommendations must be cognizant of local health care systems and resourcing considering the geographic distribution of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.